Avalo Therapeutics Inc
C6K0
Company Profile
Business description
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Contact
540 Gaither Road
Suite 400
RockvilleMD20850
USAT: +1 410 522-8707
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,158.70 | 9.80 | 0.12% |
| CAC 40 | 8,045.40 | 48.80 | -0.60% |
| DAX 40 | 22,888.19 | 110.96 | -0.48% |
| Dow JONES (US) | 41,864.60 | 88.72 | -0.21% |
| FTSE 100 | 8,652.70 | 49.29 | -0.57% |
| HKSE | 23,689.72 | 530.23 | -2.19% |
| NASDAQ | 17,685.30 | 6.32 | -0.04% |
| Nikkei 225 | 37,677.06 | 74.82 | -0.20% |
| NZX 50 Index | 12,113.54 | 58.82 | 0.49% |
| S&P 500 | 5,647.85 | 15.04 | -0.27% |
| S&P/ASX 200 | 7,931.20 | 12.30 | 0.16% |
| SSE Composite Index | 3,364.83 | 44.12 | -1.29% |